Study identifier:D6830C00003
ClinicalTrials.gov identifier:NCT06529419
EudraCT identifier:N/A
CTIS identifier:2024-514228-18-00
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults with Uncontrolled Asthma at Risk of Exacerbations (LEVANTE)
asthma
Phase 2
No
AZD8630, Placebo
All
516
Interventional
18 Years - 80 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD8630 dose A Inhaled AZD8630 administered at a dose A | Drug: AZD8630 The drug will be administered by inhalation Device: Inhaler The drug/placebo will be administered by inhalation using the inhaler |
Experimental: AZD8630 dose B Inhaled AZD8630 administered at a dose B | Drug: AZD8630 The drug will be administered by inhalation Device: Inhaler The drug/placebo will be administered by inhalation using the inhaler |
Experimental: AZD8630 dose C Inhaled AZD8630 administered at a dose C | Drug: AZD8630 The drug will be administered by inhalation Device: Inhaler The drug/placebo will be administered by inhalation using the inhaler |
Placebo Comparator: Placebo Inhaled placebo | Drug: Placebo The placebo will be administered by inhalation Device: Inhaler The drug/placebo will be administered by inhalation using the inhaler |